Home > Libri > Medicina > Ematologia > Diagnostic and management of high-risk acute myeloblastic leukemia in adult patients


Diagnostic and management of high-risk acute myeloblastic leukemia in adult patients

Roberto M. LEMOLI; Adriano VENDITTI

Copertina flessibile € 24,00  € 22,80

Acquista   Preview   Email alert   


High-risk acute myeloblastic leukemia (HR AML) is characterized by unfavorable biologic and clinical features impairing the efficacy of conventional treatments resulting in less than 40% short-term complete remission (CR) rate and poor median overall survival (OS). In addition, high-risk disease occurs, often, in elderly patients with high comorbidity burden and these findings induce poor tolerability to chemotherapy and reduced eligibility to allogeneic stem cell transplantation (HSCT), the only curative therapeutic option in this setting. Here, leading experts in the field cover all the novel aspects concerning the updated definition, the diagnosis, the management and future perspectives tor HR AML patients. Over the last decade the great progress in molecular and cell biology, medicinal chemistry far drug design and immunology have resulted in the development and approval of a large number of novel therapeutics for patients with AML. Although the definition of HR AML is evolving, the better understanding of the genetic and biological characteristics of leukemic cells and their microenviroment will significantly contribute towards novel therapeutic approaches.


Identification of high risk-AML patients

Matteo G. Della Porta, Alessia Campagna

Diagnostic procedures

Tiziana Ottone, Serena Travaglini, Luca Guarnera, Mariadomenica Divona, Paola Panetta, Carmelo Gurnari, Maria Teresa Voso

Patient-related factors: how do we define fitness?

Felicetto Ferrara

Current therapy for fit patients

Fabio Guolo, Paola Minetto, Roberto M. Lemoli

Current therapy for older/unfit patients

Luca Guarnera, Fabrizio Bonanni, Raffaele Palmieri, Adriano Venditti

Factors after diagnosis: the role of measurable resid¬ual disease

Sylvie Freeman

Allogeneic stem cell transplantation

Fabio Ciceri

Risk of infectious complications with novel therapies for high-risk acute myeloid leukemia

Luana Fianchi, Martina Quattrone, Livio Pagano

High-risk acute myeloid leukemia: from the immune microenvironment to immunotherapy

Gianluca Cristiano, Darina Ocadlikova, Antonio Curti

Emerging targeted therapies for high-risk acute myeloid leukemia

Gautam Borthakur

Emerging approaches to treat high-risk acute myeloid leukemia

Abhishek Maiti, Michael Andreeff

inizio pagina